Virus therapy trial targets untreatable superbug lung disease
NCT ID NCT07429162
Summary
This early-stage study is testing a new treatment approach for a serious, drug-resistant lung infection called Mycobacterium abscessus. The treatment combines specially engineered viruses (called bacteriophages) that target the bacteria with standard antibiotics. The goal is to see if this combination can reduce the amount of bacteria in the lungs and improve breathing and other symptoms in a single patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.